As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set ...

Alnylam Pharmaceuticals has put its dancing shoes on to raise awareness of the experience of living with acute hepatic porphyria (AHP). A recently released patient storytelling initiative by the ...

At Alnylam, we believe that making history means advancing groundbreaking science while shaping a healthier, more equitable, and sustainable future for all," said Yvonne Greenstreet, M.D., Chief ...

CAMBRIDGE, Mass., May 28, 2025--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company ...

The Cambridge drugmaker was a founding member of the nonprofit OUTbio in 2015 and has also had an affinity group called the Sexuality And Gender Alliance since 2018. Mass. companies display their ...

The court held that Alnylam had acted as its own lexicographer in defining the term “branched alkyl” in its patent specifications and that definition foreclosed Alnylam’s infringement ...

Contains New Disclosures of Company’s Impact on the Environment – Including Independently Verified Scope 1, 2, and 3 Multiyear Data on Greenhouse Gas (GHG) Emissions – – Highlights Progress of Alnylam ...

On June 2, H.C. Wainwright’s Patrick Trucchio reiterated his Buy rating on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and raised his price target from $400 to $500. His bullish view reflects ...

Regeneron and Alnylam are to research treatments for the chronic liver disease non-alcoholic steatohepatitis (NASH), under a new agreement. Alnylam specialises in treatments based around RNA ...

Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis, Alnylam has got the go-ahead for a second – Amvuttra – which has a simpler ...